New anticoagulants - Towards the development of an "ideal" anticoagulant

Vasa - Journal of Vascular Diseases

Volumn 38, Issue 1, 2009, Pages 13-29

  Haas, Sylvia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anticoagulants; Factor Xa inhibitors; Heparins; Thrombin inhibitors; Vitamin K antagonists

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9A INHIBITOR; BLOOD CLOTTING INHIBITOR; DABIGATRAN ETEXILATE; DU 176B; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; PLACEBO; RECOMBINANT NEMATODE ANTICOAGULANT PEPTIDE C2; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XARELTO; XIMELAGATRAN; YM 150; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9A; THROMBIN; VITAMIN K GROUP;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; AREA UNDER THE CURVE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ISCHEMIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORTHOPEDIC SURGERY; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SEPSIS; SINGLE DRUG DOSE; STROKE; THROMBOEMBOLISM; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG MONITORING; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DRUG ADMINISTRATION ROUTES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG MONITORING; FACTOR IXA; FACTOR XA; HEMORRHAGE; HUMANS; THROMBIN; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN K;

EID: 71049182343     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.38.1.13     Document Type: Review

References (110)

1. Abe K, Siu G,Edwards S, Lin PH, Zhu BY, Marzec U, Hanson S, Pak Y, Hollenbach S, Sinha U. Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral Factor Xa inhibitor. Blood 2006; 108: Abstract 901.
2. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28: 31-3.
3. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, singleblind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
4. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C,Tobias J,Poole L, Stolzenbach JC, Creasey AA. Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis: A Randomized Controlled Trial. JAMA 2003; 290: 238-47.
5. Agnelli G. Current issues in anticoagulation. Pathophysiol Haemost Thromb 2005; 34 (Suppl 1): 2-9.
6. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007a; 116: 180-7.
7. Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007b; 5: 746-53.
8. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 630S-69S.
9. Albers GW, Diener HC,Frison L, Grind M, Nevinson M, Partridge S, Halperin JL,Horrow J, Olsson SB, Petersen P, Vahanian A. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-8.
10. Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost 2005; 3: 439-47.
11. Amsterdam R, Faaij RA, Schoemaker RC, Maris FA, Burggraaf J, Cohen AF. The effect of age on the pharmacokinetics and effects of the long-acting synthetic pentasaccharide idraparinux sodium. 2005: 95-108.
12. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non STElevation Myocardial Infarction). Circulation 2007.
13. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of CHest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 160S-98S.
14. Antman EM, Morrow DA, Mc-Cabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-88.
15. Bauer KA, Eriksson BI, Lassen MR, and Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
16. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG. Fondaparinux, a synthetic pen tasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 37-52.
17. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
18. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 72: 1994; 381-6.
19. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
20. Bittl JA. Argatroban for percutaneous coronary interventions: Hit or miss? Catheter Cardiovasc Interv 2002; 57: 185-6.
21. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-9.
22. Bittl JA, Feit F. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am J Cardiol 1998; 82: 43P-9P.
23. Boneu B,Necciari J,Cariou R, Sie P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org 31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
24. Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Thorp-Pedersen C, Wyse DG. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial. Lancet 2008; 371: 315-21.
25. Buller HR. Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study. Eur Heart J 2006; 27 (Abstract supplement): 761.
26. Buller HR. A dose finding study of the oral direct Factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli investigators. J Thromb Haemost 2007; 5: O-S-003.
27. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-104.
28. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-73.
29. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O,Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
30. Caprini JA, Hwang E, Hantel S, Schnee J, Eriksson BI. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopaedic surgery. J Thromb Haemost 2007; 5: Abtract O-W-050.
31. Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIAPCI trial. Circulation 2007; 115: 2642-51.
32. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-73.
33. Depasse F, Busson J, Mnich J, Le Flem L, Gerotziafas GT, and Samama MM. Effect of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro. J Thromb Haemost 2005; 3: P1104.
34. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-8.
35. du Breuil AL, Umland EM. Outpatient management of anticoagulation therapy. Am Fam Physician 2007; 75: 1031-42.
36. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
37. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; a4: 121-8.
38. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006b; 114: 2374-81.
39. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
40. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR, E-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost 2007a; 5: 2175-7.
41. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, and Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, non-inferiority trial. Lancet 2007b; 370: 949-56.
42. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337-42.
43. Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kalebo P, Gaillard ML, Meems L. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb 2007c; Haemost 5: 1660-5.
44. Eriksson BI, Turpie AGG, Lassen M, Prins MH, Agnelli G, Kalebo P, Wetherill G. Once daily YM150, an oral direct Factor Xa inhibitor, for prevention of venous thromboembolism in patients undergoing elective primary hip replacement. Blood 2007d; 110: Abstract 309. Oral presentation at ASH 2007.
45. Ezekowitz MD, Reilly P, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L. Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients with Nonvalvular Atrial Fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-26.
46. Faaij RA, Burggraaf J, Amsterdam R, Schoemaker RC, Maris FA, Cohen AF. A phase I single rising dose study to investigate the safety, tolerability and pharmacokinetics of idraparinux sodium in healthy young volunteers. 2005: 79-94.
47. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-9.
48. Friedman RJ, Caprini JA, Comp PC, Davidson BL, Francis CW, Ginsberg J, Huo M, Lieberman JR, Muntz J, Raskob G, Clements ML, Hantel S, Schnee J. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty (RE-MOBILIZE). J Thromb Haemost 2007; 5.
49. Fujii Y, Takahashi M, Morita H, Kikuchi H, Aramaki Y, and Amidon GL. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant. Drug Metab Pharmacokinet 2007; 22: 26-32.
50. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 381S-453S.
51. Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Leesar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEMTIMI-32 trial. J Am Coll Cardiol 2007; 49: 2398-407.
52. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
53. Haas S. Medical indications and considerations for future clinical decision making. Thromb Res 2003; 109: S31.
54. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg PG, Guyatt GH, and Goodman SG. Antithrombotic therapy for non ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 670S-707S.
55. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
56. He K, He B, Grace JE, Xin B, Zhang D, Pinto DJ, Luettgen JM, Knabb RM, Lam PY, Wexler RR, Humphreys WG, Shyu W. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective Factor Xa inhibitor. Blood 2006; 108: Abstract 910.
57. Heparin Help Center. Heparin contamination. Available online from: http://www.heparinhelpcenter.com/heparin/heparincontaminationhtml. 2008.
58. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 2006; 22: 471-81.
59. Hinder M, Frick A, Rosenburg R, Hesse G, Ozoux ML, Laux V, Scholtz H, Gebauer A, Paccaly A. Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. Thromb Haemost 2006; 95: 224-8.
60. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, and Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 141S-59S.
61. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-60.
62. Hirsh J, O'Donnell M, and Weitz JI. New anticoagulants. Blood 2005; 105: 453-63.
63. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
64. Howard EL, Becker KC, Rusconi CP, Becker RC. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007; 27: 722-7.
65. Iwatsuki Y, Shigenaga T, Moritani Y, Suzuki M, Ishihara T, Hirayama F, Kawasaki T. Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor. Blood 2006; 108: Abstract 911.
66. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a doubleblind, randomised controlled trial. Lancet 2008; 372: 31-9.
67. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, and Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest PHysicians evidencebased clinical practice guidelinse (8th Edition). Chest 2008; 133: 454S-545S.
68. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor. Blood 2006; 108: Abstract 905.
69. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005a; 78: 412-21.
70. Kubitza D, Becka M,Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005b; 61: 873-80.
71. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006; 15: 843-55.
72. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel T-J, Misselwitz F, Turpie AG. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-85.
73. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
74. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-75.
75. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Esperance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124: 619-26.
76. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van der Meer J, Piovella F, Raskob G, Gent M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-8.
77. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ, Jay RM, Neemeh J. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114: 545-51.
78. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995; 74: 1474-7.
79. Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, Budaj A, Joyner C, Chrolavicius S, Fox KA. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2005; 150: 1107.
80. Morabia A. Heparin doses and major bleedings. Lancet 1986; 1: 1278-9.
81. Morishima Y, Furugohri T, Honda Y, Matsumoto C, Isobe K, Fukuda T, Shiozaki Y, Muramatsu S, Sugiyama N, Shibano T. Antithrombotic properties of DU-176b, a novel orally active Factor Xa inhibitor: inhibition of both arterial and venous thrombosis, and combination effects with other antithrombotic agents. J Thromb Haemost 2005; 3: PO511.
82. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335-44.
83. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kalebo P, Kwong LM, Misselwitz F, Turpie AG. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-16.
84. Murayama N, Tanaka M, Kunitada S, Yamada H, Inoue T, Terada Y, Fujita M, Ikeda Y. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1999; 66: 258-64.
85. Oldgren J, Wallentin L, Afzal R, Bassand JP, Budaj A, Chrolavicius S, Fox KA, Granger CB, Mehta SR, Pais P, Peters RJ, Xavier D, Zhu J, Yusuf S. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 2008; 29: 315-23.
86. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8.
87. Paccaly A, Ozoux ML, Chu V, Simcox K, Marks V, Freyburger G, Sibille M, Shukla U. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost 2005; 94: 1156-63.
88. Paccaly A, Frick A, Rohatagi S, Liu J, Shukla U, Rosenburg R, Hinder M, Jensen BK. Pharmacokinetics of otamixaban, a direct Factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/ 3 simulation of exposure. J Clin Pharmacol 2006; 46: 37-44.
89. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, and Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
90. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PY. Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa. J Med Chem 2007; 50: 5339-56.
91. Schulman S, Beyth RJ,Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 257S-98S.
92. Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg 1998; 115: 1179-88.
93. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
94. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59.
95. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997-1003.
96. The Petro-Ex Investigators. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation. Cerebrovasc Dis 2006; 21: Abstract 5.
97. Troconiz IF, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007; 47: 371-82.
98. Turpie AG. Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. Am J Surg 1991; 161: 532-6.
99. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
100. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479-86.
101. Turpie AG, Gent M, Bauer K, Davidson BL, Fisher WD, Huo M, Borow K. Evaluation of the Factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT). J Thromb Haemost 2007; 5: P-T-652.
102. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
103. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11: 397-407.
104. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparininduced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
105. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-8.
106. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 1843-53.
107. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
108. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM. Apixaban, an oral, direct and highly selective Factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost E-pub ahead of print: 2008.
109. Yusuf S,Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519-30.
110. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M,Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98: 883-8.